PDCD1 and melanoma: This two‐part, open‐label, multicenter, phase 1b study in adults with metastatic/unresectable anti–PD‐1–resistant melanoma evaluated the safety and clinical activity of intratumoral vidutolimod plus systemic pembrolizumab (part 1) or vidutolimod alone (part 2).